Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.